当无法获得倍他米松和地塞米松时：使用氢化可的松。

When betamethasone and dexamethasone are unavailable: hydrocortisone.

作者信息

Moore L E, Martin J N

机构信息

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216-4505, USA.

出版信息

J Perinatol. 2001 Oct-Nov;21(7):456-8. doi: 10.1038/sj.jp.7210601.

DOI:10.1038/sj.jp.7210601

PMID:11894514

Abstract

OBJECTIVE

To review the literature on alternatives to betamethasone and dexamethasone for enhancement of fetal lung maturity.

STUDY DESIGN

A medline search was conducted from 1966 to the present. Trials dealing with enhancement of fetal lung maturity using modalities other than betamethasone or dexamethasone were reviewed.

RESULTS

Eight studies met inclusion criteria. Excluding betamethasone and dexamethasone, the most frequently studied glucocorticoids, for fetal lung maturation, are methylprednisolone and hydrocortisone. Methylprednisolone does not cross the placenta. Two grams of hydrocortisone has been shown to improve indices of fetal lung maturity (i.e., L/S ratio) and to improve fetal outcomes compared to no treatment.

CONCLUSION

There is limited information about alternatives to betamethasone and dexamethasone for the enhancement of fetal lung maturity in women at risk of preterm delivery. In the absence of these two preferred drugs, hydrocortisone can be given at a dose of 500 mg intravenously every 12 hours for four doses for this indication.

摘要